MORRISTOWN, N.J., June 15, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (Nasdaq:PTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman, President and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, are scheduled to present at the JMP Securities Life Sciences Conference as follows:
|Date:||Tuesday, June 23, 2015|
|Time:||1:00 p.m. EDT|
|Location:||The St. Regis New York|
The presentation will be webcast and available on the Investors section of the Company's website at http://www.pernixtx.com/investors/webcasts-presentations/. A replay of the webcast will be available for 30 days after the date of the presentation.
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
CONTACT: Investor Relations Lisa Wilson, (212) 452-2793 In-Site Communications email@example.com Media Relations Marianne Lambertson, (800) 793-2145 ext. 1012 Vice President, Marketing & Corporate Communications firstname.lastname@example.org
Source:Pernix Therapeutics, Inc.